Evidence map›Paper›PMID 36191870›Full record

ArticleThe American journal of tropical medicine and hygiene2022

Simulating the Impacts of Augmenting Intensive Vector Control with Mass Drug Administration or Test-and-Treat Strategies on the Malaria Infectious Reservoir.

Joaniter I Nankabirwa, Emmanuel Arinaitwe, Jessica Briggs, John Rek, Philip J Rosenthal, Moses R Kamya, Peter Olwoch, David L Smith, Isabel Rodriguez-Barraquer, Grant Dorsey and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Joaniter I NankabirwaDepartment of Internal Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Emmanuel ArinaitweInfectious Disease Research Collaboration, Kampala, Uganda.
Jessica BriggsDepartment of Infectious Diseases, School of Medicine, University of California, San Francisco, California.
John RekInfectious Disease Research Collaboration, Kampala, Uganda.
Philip J RosenthalDepartment of Infectious Diseases, School of Medicine, University of California, San Francisco, California.
Moses R KamyaDepartment of Internal Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Peter OlwochInfectious Disease Research Collaboration, Kampala, Uganda.
David L SmithDepartment of Health Metrics Sciences, University of Washington, Seattle, Washington.
Isabel Rodriguez-BarraquerDepartment of Infectious Diseases, School of Medicine, University of California, San Francisco, California.
Grant DorseyDepartment of Infectious Diseases, School of Medicine, University of California, San Francisco, California.
Bryan GreenhouseDepartment of Infectious Diseases, School of Medicine, University of California, San Francisco, California.
Infectious Diseases Research Collaboration · UGUniversity of California, San Francisco · USInstitute for Health Metrics and Evaluation · US

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joaniter Immaculate Nankabirwa · 2010 to 2026
$29.3M
Training in malaria surveillance, epidemiology and implementation science research to strengthen malaria policy and control in UgandaD43TW010526 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2017 to 2026
$2.3M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Improving the accuracy of malaria surveillance with serology and parasite genetic dataK23AI166009 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jessica Briggs · 2022 to 2026
$955k
Translational Studies of Plasmodium Falciparum Infection DynamicsK23AI076614 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENHOUSE, BRYAN R · 2008 to 2012
$609k
Impact of malaria control interventions on the infectious reservoir, host immunity, and drug resistance in UgandaK43TW010365 · FIC · INFECTIOUS DISEASES RES COLLABORATION · PI NANKABIRWA, JOANITER IMMACULATE · 2017 to 2021
$514k
FIC NIH HHS D43 TW010526FIC NIH HHS K43 TW010365NIAID NIH HHS K23 AI076614NIAID NIH HHS K23 AI166009NIAID NIH HHS K24 AI144048NIAID NIH HHS U19 AI089674
6 · The paper itself

Abstract

Highly effective vector control can reduce malaria burden significantly, but individuals with parasitemia provide a potential reservoir for onward transmission. We performed an empirical, non-parametric simulation based on cohort data from Tororo District, Uganda-an area with historically high but recently reduced malaria transmission-to estimate the effects of mass drug administration (MDA) and test-and-treat on parasite prevalence. We estimate that a single round of MDA would have accelerated declines in parasite prevalence dramatically over 2 years (cumulative parasite prevalence ratio [PPR], 0.34). This decline was mostly during the first year of administration (PPR, 0.23) and waned by 23 months (PPR, 0.74). Test-and-treat using a highly sensitive diagnostic had nearly the same effect as MDA at 1 year (PPR, 0.27) and required many fewer treatments. The impact of test-and-treat using a standard diagnostic was modest (PPR, 0.58 at 1 year). Our analysis suggests that in areas experiencing a dramatic reduction in malaria prevalence, MDA or test-and-treat with a highly sensitive diagnostic may be an effective way of reducing or eliminating the infectious reservoir temporarily. However, for sustained benefits, repeated rounds of the intervention or additional interventions are required.

Indexed as

AntimalarialsMalariaMalaria, FalciparumHumansMass Drug AdministrationParasitemiaPrevalenceUgandaAntimalarials

Identifiers

PMID36191870
PMCPMC9709029
OpenAlexW4300862935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.